🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

448 results for “RAD” Clear

  1. LENVIMA 4 mg hard capsules

    Pari Pharma GmbH

    Patients with Biopsy-proven or radiologically-suggested BCLC A HCC eligible for PA and comprising at least one of the following criteria: - Single tumour>3 cm≤ 5cm or - multiple tumours (max 3 lesions ≤ 3cm) or - Single tumour between 2 and 3 cm with at least one of the following characteristic: • Serum AFP>100 ng/mL • Infiltrative form • Macro-trabecular subtype (if applicable)

    phase 2 small molecule active

    1 trial

  2. La composición cualitativa y cuantitativa de cada sobre de placebo es la siguiente: Bicarbonato sódico 563,75 mg Diluyente/generador de efervescencia Ph Eur Ácido cítrico 410,0 mg Diluyente/generador de efervescencia Ph Eur Maltodextrina 651,25 mg Diluyente Ph Eur Sílice coloidal anhidra 10,0 mg Fluidificante/desecante interno Ph Eur Manitol 769,0 mg Diluyente Ph Eur Sacarina sódica 24,0 mg Edulcorante Ph Eur Aroma de naranja 72,0 mg Saborizante Espec.. interna Masa nominal 2.500 mg El polvo efervescente se

    The George Institute

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 small molecule active

    1 trial

  3. Lenvatinib, Lenvatinib, Lenvatinib

    Merck Sharp and Dohme

    Between ages 2 and 21 and have High Grade Glioma (HGG), Rhabdomyosarcoma (RMS), Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (pPNET), or other solid tumor types (except osteosarcoma)

    phase 2 small molecule active

    1 trial

  4. Leucovorin 10 mg/ml Lösung zur Injektion/ Infusion, TAXOTERE 20 mg/1 ml concentrate for solution for infusion, medoxa 5 mg/ml Konzentrat zur Herstellung einer Infusionslösung, IMFINZI 50 mg/mL concentrate for solution for infusion., 5-FU medac 50 mg/ml, Injektionslösung

    The George Institute

    T1-T2N0 esophageal adenocarcinoma including gastroesophageal junction (GEJ) with indication for radical surgery

    phase 2 small molecule active

    1 trial

  5. Levact 2,5 mg/ml, polvo para concentrado para solución para perfusión., Beneflur10 mg comprimidos recubiertos con película, RoActemra 20 mg/mL concentrate for solution for infusion, Genoxal 200 mg polvo para solución inyectable y para perfusión, HSP-CAR19M

    The George Institute

    Relapsed/refractory large B-cell non-Hodgkin lymphoma, mantle cell lymphoma, and follicular lymphoma

    phase 2 small molecule active

    1 trial

  6. Low Dose GC4419: 30mg/day

    Galera Therapeutics

    Radiation Induced Oral Mucositis

    phase 2 small molecule completed

    1 trial

  7. Luminity 150 microlitres/ml gas and solvent for dispersion for injection/infusion, TEMOZOLOMIDE , LOMUSTINE

    Pari Pharma GmbH

    Newly diagnosed Glioblastoma (IDH wild-type) patients at initial radiological diagnosis eligible for tumor resection, and for the standard of care including concurrent temoradiation followed by adjuvant TMZ with or without Tumor Treating Fields*. (*Tumor Treating Fields is applicable only in participating centers in France)

    phase 2 small molecule active

    1 trial

  8. MRG003

    Shanghai University of Traditional Chinese Medicine

    Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

    phase 2 small molecule active

    1 trial

  9. Memantine Oral Tablet

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Radiation Disease

    phase 2 small molecule active

    1 trial

  10. N-Acetylcysteine (NAC)

    CUMBERLAND PHARMACEUTICALS INC

    Radiocontrast Nephropathy

    phase 2 small molecule completed

    1 trial

  11. NORETHISTERONE AND ETHINYLESTRADIOL , IDE196 (LXS196), IDE196 (LXS196), METFORMIN HYDROCHLORIDE

    IDEAYA Biosciences

    Uveal Melanoma

    phase 2 small molecule active

    1 trial

  12. Neoadjuvant Chemotherapy

    Xiangya Hospital of Central South University

    High-Grade Upper Tract Urothelial Carcinoma

    phase 2 small molecule completed

    1 trial

  13. Neoadjuvant Chemotherapy combined with Neoadjuvant Radiotherapy

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 other active

    1 trial

  14. Nestorone/ethinyl estradiol contraceptive vaginal ring; levonorgestrel/ethinyl estradiol oral contraceptive

    United Therapeutics Europe Ltd

    Contraception

    phase 2 small molecule completed

    1 trial

  15. Nimotuzumab combined with chemoradiotherapy

    The First People's Hospital of Lianyungang

    Pancreatic Cancer Non-resectable

    phase 2 small molecule active

    1 trial

  16. OLAPARIB, BEVACIZUMAB

    The George Institute

    Advanced FIGO Stage III‐IV High Grade Serous or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer

    phase 2 small molecule active

    1 trial

  17. Ocrevus 300 mg concentrate for solution for infusion, CYTARABINE, CARMUSTINE, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE, Tysabri 300 mg concentrate for solution for infusion, CARMUSTINE, ETOPOSIDE, CARMUSTINE, UBLITUXIMAB, MELPHALAN FLUFENAMIDE, FILGRASTIM, FILGRASTIM, CYTARABINE, CYTARABINE, CYCLOPHOSPHAMIDE, RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN, Kesimpta 20 mg solution for injection in pre-filled pen, ANTI-HUMAN T-LYMPHOCYTE IMMUNOGLOBULIN FROM RABBITS, CYTARABINE, LEMTRADA 12 mg concentrate for solution f

    Fondazione Telethon ETS

    Relapsing Remitting Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  18. Olutasidenib + TMZ

    RIGEL PHARMACEUTICALS INC

    High Grade Glioma

    phase 2 small molecule active

    1 trial

  19. Omomyc

    The George Institute

    Advanced High-Grade Osteosarcoma

    phase 2 small molecule active

    1 trial

  20. Online adaptive SBRT

    Sun Yat-sen University

    Adaptive Radiotherapy

    phase 2 other active

    1 trial

  21. PACLITAXEL, LIBTAYO 350 mg concentrate for solution for infusion., CARBOPLATIN

    CERO THERAPEUTICS HOLDINGS, INC.

    Unresectable stage III Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  22. PALBOCICLIB, Zoladex 3,6 mg implante en jeringa precargada, AZD8421, PALBOCICLIB, AZD8421, PALBOCICLIB, PALBOCICLIB, RIBOCICLIB, Camizestrant, PALBOCICLIB, ABEMACICLIB, PALBOCICLIB, ABEMACICLIB, AZD8421, ABEMACICLIB

    AstraZeneca AB

    Patients with ER+ HER2- advanced breast cancer and patients with high-grade serious ovarian cancer (HGSOC)

    phase 2 small molecule active

    1 trial

  23. PD -1/PD-L1 monoclonal antibody plus radiotherapy and liver transplantation

    The First People's Hospital of Lianyungang

    Locally Advanced Perihilar Cholangiocarcinoma

    phase 2 other active

    1 trial

  24. PEMBROLIZUMAB, OLAPARIB, OLAPARIB

    The George Institute

    patients with unresectable or metastatic HER2 negative breast cancer and a deleterious germline mutation in BRCA 1/2, ATM, BARD1, CHEK2, FANCC, PALB2, RAD51C, RAD51D, SLX4, XRCC2 or a homologous recombination deficiency

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources